Myeloma : nature.com subject feeds
Myeloma research on the move
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma
Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma
Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma
Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement
MajesTEC results with teclistamab in RRMM
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma
Treatment and outcomes of POEMS syndrome: changes in the past 20 years
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma
Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders
Correction: C3a and C5a facilitates the metastasis of myeloma cells by activating Nrf2
Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma
Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length
Feed Fetched by RSS Dog.